Related Experiment Video

Updated: Aug 14, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Antitumor effect of IL-2, p53, and bax gene transfer in C6 glioma cells

P Haghighat1, T M Timiryasova, B Chen

  • 1Center for Molecular Biology and Gene Therapy, Loma Linda University School of Medicine, CA 92350, USA.

Anticancer Research
|August 6, 2000
PubMed

Insights

This study explored gene therapy for glioma using interleukin-2 (IL-2), p53, and bax genes. Bax gene therapy significantly reduced tumor volume in mice, showing promise for glioma treatment.

Area of Science:

  • Oncology
  • Gene Therapy
  • Immunotherapy

Background:

  • Interleukin-2 (IL-2) and p53 are investigated for cancer immunotherapy and gene therapy.
  • Previous research indicates potential benefits of IL-2 and p53 in cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy of plasmid gene therapy using murine IL-2, wild-type human p53, and murine bax genes in C6 glioma-bearing nude mice.
  • To assess the antitumor activity and safety of individual and combined gene therapies.

Main Methods:

  • In vitro assays and immunocytochemical analysis confirmed protein expression in transfected C6 cells.
  • Nude mice with established subcutaneous C6 glioma were treated with naked plasmid DNA encoding IL-2, p53, bax, or combinations thereof.
  • Tumor volume and progression were monitored in vivo.

Main Results:

  • Significant antitumor activity was observed in groups treated with IL-2, p53/IL-2, and bax.
  • The bax gene demonstrated a significant reduction in tumor volume compared to p53 (p < 0.02).
  • No synergistic effect was found for the p53/IL-2 combination therapy.

Conclusions:

  • Naked gene delivery of IL-2, p53, and bax is safe for glioma treatment in vivo.
  • Bax gene therapy shows significant efficacy in reducing glioma tumor volume.
  • Gene therapy holds promise for slowing glioma progression in athymic rodents.

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.